Statera Biopharma, Inc. announced the resignation of Peter Aronstam as Chief Financial Officer, effective from May 27, 2022. The Board of Directors of the Company has commenced a search for a new Chief Financial Officer.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0006 USD | -.--% | -14.29% | -.--% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 43.55K | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. Announces Resignation of Peter Aronstam as Chief Financial Officer